🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the battle against superbug strains of the infection, according to health experts.

A Worldwide Public Health Issue

Cases of gonorrhoea are increasing globally, with figures suggesting over 82 million infections per year. Notably increased rates are seen in the African continent and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune step in the reality of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Public health authorities are particularly alarmed about the rise in drug-resistant strains. The World Health Organization has designated it as a "priority pathogen". Ongoing monitoring revealed that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Treatment Options Receive Clearance

Zoliflodacin, alternatively called a brand name, was authorized by the US Food and Drug Administration in December for treating gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Researchers believe that specific application of this new drug will help slow the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This medication, which is also used to treat UTIs, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to see it through.

“This approval marks a huge turning point in the therapy of highly resistant gonorrhoea, which previously has been evolving faster than antibiotic development.”

Research Study Results and Global Access

Based on data detailed in a major medical journal, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the current standard treatment, which uses a dual-drug approach. The study included nearly 1,000 patients from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the authority to make available and distribute the drug in many regions with limited resources.

Clinicians treating patients have voiced positive views. The availability of a one-pill regimen such as this is hailed as a "revolutionary step" for gonorrhoea control. This is viewed as essential to reduce the burden of the disease for patients and to stop the proliferation of extremely resistant gonorrhoea globally.